Oral Wegovy reaches French pharmacies with access limits
The once-daily prescription tablet arrived on 2 November as an alternative to weekly injections, but the oral form launched without French health-insurance reimbursement.
An oral form of Wegovy became available in French pharmacies on 2 November, giving eligible adults a once-daily tablet alternative to the medicine’s weekly injection. It remains a prescription treatment for obesity or overweight with specified weight-related conditions, not a general slimming product.
The European Medicines Agency describes it as the first oral GLP-1 receptor agonist authorised for weight management in the European Union. Its guidance says the tablet is taken on an empty stomach after at least eight hours of fasting, followed by a 30-minute wait before food, drink or other medicines. Patients should follow the prescribed instructions rather than treat those details as self-care advice.
Available does not mean reimbursed
Access is not the same as reimbursement. Le Parisien reported that the oral form launched in France without coverage by national health insurance and with a manufacturer-recommended monthly price of €169. Pharmacy prices can differ, and a reported launch price is not a guarantee of what every patient will pay.
The reimbursement position also differs by formulation and eligibility. Since June, France has covered certain GLP-1 weight-management medicines, including injectable Wegovy, for adults meeting strict severity criteria within a structured care pathway. That policy does not mean the newly launched tablet is automatically covered.
What the evidence does and does not say
EMA’s authorisation was based on a phase-three trial in 307 adults. The agency reported average weight loss of 13.61 percent after 64 weeks with the tablet, compared with 2.18 percent with placebo, alongside diet and physical activity. Trial averages do not predict an individual outcome.
The agency lists gastrointestinal disorders, including nausea, diarrhoea, constipation, abdominal pain and vomiting, as the most common adverse effects. Dose escalation and clinical follow-up are part of safe use. Availability in a pharmacy does not remove the need for a doctor to assess indications, contraindications and other medicines.
A format change, not self-service medicine
The French launch is therefore an access and format change, not a replacement for medical care. The questions to watch are supply, real pharmacy pricing, any future reimbursement decision and how prescribers select between tablet and injection. Patients should seek individual advice from a qualified clinician or pharmacist.
Sources & context
Reporting and reference material used for this article. Context sources do not independently confirm every news claim.
- European Medicines Agency ↗Primary regulatory material, published in 2026: indication, dosing conditions, trial results and common adverse effects.
- French Health Ministry ↗Primary policy context, published 12 June 2026: prescription pathway and reimbursement criteria for covered weight-management medicines.
- Le Parisien ↗Independent reporting, published 28 October 2026: French launch date, prescription status, non-reimbursement and recommended price.
- TF1 Info ↗Independent reporting, published 1 November 2026: pharmacy availability, daily administration and pricing context.
Written for WHIF from the linked material. This article does not claim on-the-ground reporting. Our editorial standards.